Jane Street Group LLC Grows Stock Holdings in AVITA Medical, Inc. (NASDAQ:RCEL)

Jane Street Group LLC grew its position in AVITA Medical, Inc. (NASDAQ:RCEL) by 32.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 89,395 shares of the company’s stock after buying an additional 22,032 shares during the period. Jane Street Group LLC owned 0.34% of AVITA Medical worth $958,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of RCEL. Essex Investment Management Co. LLC acquired a new stake in shares of AVITA Medical in the 3rd quarter worth $2,477,000. State Street Corp boosted its holdings in AVITA Medical by 2.4% in the third quarter. State Street Corp now owns 519,997 shares of the company’s stock worth $5,574,000 after acquiring an additional 11,997 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of AVITA Medical during the second quarter worth about $86,000. IHT Wealth Management LLC increased its holdings in shares of AVITA Medical by 24.3% during the third quarter. IHT Wealth Management LLC now owns 28,100 shares of the company’s stock valued at $301,000 after acquiring an additional 5,500 shares in the last quarter. Finally, Quest Partners LLC increased its holdings in shares of AVITA Medical by 269.4% during the third quarter. Quest Partners LLC now owns 7,520 shares of the company’s stock valued at $81,000 after acquiring an additional 5,484 shares in the last quarter. Institutional investors own 27.66% of the company’s stock.

AVITA Medical Trading Down 3.1 %

Shares of AVITA Medical stock opened at $12.80 on Wednesday. The stock has a market cap of $335.59 million, a PE ratio of -5.74 and a beta of 1.60. The firm has a fifty day moving average price of $12.21 and a 200 day moving average price of $10.39. AVITA Medical, Inc. has a 1 year low of $7.51 and a 1 year high of $18.93. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.73 and a quick ratio of 3.37.

AVITA Medical (NASDAQ:RCEL) last issued its earnings results on Thursday, November 7th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.21). The company had revenue of $19.55 million during the quarter, compared to analysts’ expectations of $19.65 million. AVITA Medical had a negative return on equity of 194.69% and a negative net margin of 95.47%. During the same quarter in the previous year, the company earned ($0.34) EPS. Equities research analysts predict that AVITA Medical, Inc. will post -2.35 earnings per share for the current year.

Wall Street Analyst Weigh In

RCEL has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 target price on shares of AVITA Medical in a research report on Tuesday, December 24th. D. Boral Capital started coverage on AVITA Medical in a research report on Tuesday, December 24th. They set a “buy” rating and a $25.00 price target for the company. Finally, Piper Sandler restated a “neutral” rating and issued a $12.00 price objective (up from $9.00) on shares of AVITA Medical in a research note on Friday, November 8th.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.